Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation
In the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial conducted by White et al. (March 29 issue from NEJM), all-cause mortality and cardiovascular mortality are found to be higher among patients randomly assigned to febuxostat c...
Gespeichert in:
| Veröffentlicht in: | Clinical rheumatology 2019-01, Vol.38 (1), p.263-265 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 265 |
|---|---|
| container_issue | 1 |
| container_start_page | 263 |
| container_title | Clinical rheumatology |
| container_volume | 38 |
| creator | Jansen, Tim L. Th. A. Janssen, Matthijs |
| description | In the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial conducted by White et al. (March 29 issue from NEJM), all-cause mortality and cardiovascular mortality are found to be higher among patients randomly assigned to febuxostat compared to allopurinol, but significant flaws are a clear lack of treat to target strategy with more powered treatment in the febuxostat arm, dysbalance with cardiovascular risk factors selectively in again the febuxostat arm, and discontinuation of the trial regimen in over 50% of patients with discontinuation of follow-up in about 45%. With these flaws, conclusions such as febuxostat-associated higher mortality are potentially if not probably incorrect, and thus febuxostat to be used not as first-line therapy may well be an invalid consequence? The paper here describes potential lessons to be taken. |
| doi_str_mv | 10.1007/s10067-018-4396-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2155910707</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2154899473</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-1f7f4d931f2ec1877350b9b5ef6cb3a61fe8c58be8b93cd123c23317a24b35993</originalsourceid><addsrcrecordid>eNp1kcFuEzEQhi1URNPAA3BBlnrpgQWP7Y3t3qKotJUiKkE5r2yvjdx618HerehD8M44SgEJqZeZw3z_P6P5EXoL5AMQIj6WWleiISAbztSq4S_QAjjjjVJcHaEFEYI0DJQ8Riel3BFCqFTwCh0z0nIqlFygX5dpnnB0paSxYJ_TgGn1O8eb9ZeLr--xxn3Izk7YpmGnc6gYTh57Z-afqUx6wg8F6xjTbs5hTLEqxr6KP9_eVPX1FrCJyd67jH3K2Orch_Sgi52jzrja3eMhjGEIRU8hja_RS69jcW-e-hJ9-3Rxu7lqtjeX15v1trFMyakBLzzvFQNPnQUpBGuJUaZ1fmUN0yvwTtpWGieNYrYHyixlDISm3LBWKbZEZwffXU4_Zlemrl5gXYx6dGkuHYW2VUAEERU9_Q-9S3Me63V7isv6asEqBQfK5lRKdr7b5TDo_NgB6fZZdYesuvrbbp9VLUv07sl5NoPr_yr-hFMBegBKHY3fXf63-nnX36SZnhY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2154899473</pqid></control><display><type>article</type><title>Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation</title><source>SpringerLink Journals</source><creator>Jansen, Tim L. Th. A. ; Janssen, Matthijs</creator><creatorcontrib>Jansen, Tim L. Th. A. ; Janssen, Matthijs</creatorcontrib><description>In the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial conducted by White et al. (March 29 issue from NEJM), all-cause mortality and cardiovascular mortality are found to be higher among patients randomly assigned to febuxostat compared to allopurinol, but significant flaws are a clear lack of treat to target strategy with more powered treatment in the febuxostat arm, dysbalance with cardiovascular risk factors selectively in again the febuxostat arm, and discontinuation of the trial regimen in over 50% of patients with discontinuation of follow-up in about 45%. With these flaws, conclusions such as febuxostat-associated higher mortality are potentially if not probably incorrect, and thus febuxostat to be used not as first-line therapy may well be an invalid consequence? The paper here describes potential lessons to be taken.</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-018-4396-4</identifier><identifier>PMID: 30542798</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Allopurinol ; Cardiovascular diseases ; Gout ; Health risk assessment ; Interleukin 1 ; Letter to the Editor ; Medicine ; Medicine & Public Health ; Mortality ; Patients ; Rheumatology ; Risk factors</subject><ispartof>Clinical rheumatology, 2019-01, Vol.38 (1), p.263-265</ispartof><rights>International League of Associations for Rheumatology (ILAR) 2018</rights><rights>Clinical Rheumatology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-1f7f4d931f2ec1877350b9b5ef6cb3a61fe8c58be8b93cd123c23317a24b35993</citedby><cites>FETCH-LOGICAL-c398t-1f7f4d931f2ec1877350b9b5ef6cb3a61fe8c58be8b93cd123c23317a24b35993</cites><orcidid>0000-0003-3026-3154</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10067-018-4396-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10067-018-4396-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30542798$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jansen, Tim L. Th. A.</creatorcontrib><creatorcontrib>Janssen, Matthijs</creatorcontrib><title>Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><addtitle>Clin Rheumatol</addtitle><description>In the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial conducted by White et al. (March 29 issue from NEJM), all-cause mortality and cardiovascular mortality are found to be higher among patients randomly assigned to febuxostat compared to allopurinol, but significant flaws are a clear lack of treat to target strategy with more powered treatment in the febuxostat arm, dysbalance with cardiovascular risk factors selectively in again the febuxostat arm, and discontinuation of the trial regimen in over 50% of patients with discontinuation of follow-up in about 45%. With these flaws, conclusions such as febuxostat-associated higher mortality are potentially if not probably incorrect, and thus febuxostat to be used not as first-line therapy may well be an invalid consequence? The paper here describes potential lessons to be taken.</description><subject>Allopurinol</subject><subject>Cardiovascular diseases</subject><subject>Gout</subject><subject>Health risk assessment</subject><subject>Interleukin 1</subject><subject>Letter to the Editor</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mortality</subject><subject>Patients</subject><subject>Rheumatology</subject><subject>Risk factors</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kcFuEzEQhi1URNPAA3BBlnrpgQWP7Y3t3qKotJUiKkE5r2yvjdx618HerehD8M44SgEJqZeZw3z_P6P5EXoL5AMQIj6WWleiISAbztSq4S_QAjjjjVJcHaEFEYI0DJQ8Riel3BFCqFTwCh0z0nIqlFygX5dpnnB0paSxYJ_TgGn1O8eb9ZeLr--xxn3Izk7YpmGnc6gYTh57Z-afqUx6wg8F6xjTbs5hTLEqxr6KP9_eVPX1FrCJyd67jH3K2Orch_Sgi52jzrja3eMhjGEIRU8hja_RS69jcW-e-hJ9-3Rxu7lqtjeX15v1trFMyakBLzzvFQNPnQUpBGuJUaZ1fmUN0yvwTtpWGieNYrYHyixlDISm3LBWKbZEZwffXU4_Zlemrl5gXYx6dGkuHYW2VUAEERU9_Q-9S3Me63V7isv6asEqBQfK5lRKdr7b5TDo_NgB6fZZdYesuvrbbp9VLUv07sl5NoPr_yr-hFMBegBKHY3fXf63-nnX36SZnhY</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Jansen, Tim L. Th. A.</creator><creator>Janssen, Matthijs</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3026-3154</orcidid></search><sort><creationdate>20190101</creationdate><title>Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation</title><author>Jansen, Tim L. Th. A. ; Janssen, Matthijs</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-1f7f4d931f2ec1877350b9b5ef6cb3a61fe8c58be8b93cd123c23317a24b35993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Allopurinol</topic><topic>Cardiovascular diseases</topic><topic>Gout</topic><topic>Health risk assessment</topic><topic>Interleukin 1</topic><topic>Letter to the Editor</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mortality</topic><topic>Patients</topic><topic>Rheumatology</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jansen, Tim L. Th. A.</creatorcontrib><creatorcontrib>Janssen, Matthijs</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jansen, Tim L. Th. A.</au><au>Janssen, Matthijs</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><addtitle>Clin Rheumatol</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>38</volume><issue>1</issue><spage>263</spage><epage>265</epage><pages>263-265</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>In the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial conducted by White et al. (March 29 issue from NEJM), all-cause mortality and cardiovascular mortality are found to be higher among patients randomly assigned to febuxostat compared to allopurinol, but significant flaws are a clear lack of treat to target strategy with more powered treatment in the febuxostat arm, dysbalance with cardiovascular risk factors selectively in again the febuxostat arm, and discontinuation of the trial regimen in over 50% of patients with discontinuation of follow-up in about 45%. With these flaws, conclusions such as febuxostat-associated higher mortality are potentially if not probably incorrect, and thus febuxostat to be used not as first-line therapy may well be an invalid consequence? The paper here describes potential lessons to be taken.</abstract><cop>London</cop><pub>Springer London</pub><pmid>30542798</pmid><doi>10.1007/s10067-018-4396-4</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0003-3026-3154</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0770-3198 |
| ispartof | Clinical rheumatology, 2019-01, Vol.38 (1), p.263-265 |
| issn | 0770-3198 1434-9949 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2155910707 |
| source | SpringerLink Journals |
| subjects | Allopurinol Cardiovascular diseases Gout Health risk assessment Interleukin 1 Letter to the Editor Medicine Medicine & Public Health Mortality Patients Rheumatology Risk factors |
| title | Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A53%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gout%20lessons%20from%202018:%20CARES,%20a%20direct%20comparison%20of%20febuxostat%20vs%20allopurinol,%20and%20CANTOS,%20IL1%20blocker%20for%20cardiovascular%20risk%20minimisation&rft.jtitle=Clinical%20rheumatology&rft.au=Jansen,%20Tim%20L.%20Th.%20A.&rft.date=2019-01-01&rft.volume=38&rft.issue=1&rft.spage=263&rft.epage=265&rft.pages=263-265&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-018-4396-4&rft_dat=%3Cproquest_cross%3E2154899473%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2154899473&rft_id=info:pmid/30542798&rfr_iscdi=true |